AN2 Therapeutics (ANTX) Common Equity (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Common Equity for 6 consecutive years, with $81.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 11.5% year-over-year to $81.8 million; the TTM figure through Mar 2026 stood at $81.8 million (up 11.5% YoY), while the FY2025 annual figure was $53.1 million, down 35.17% from the prior year.
• Common Equity rose to $81.8 million in Q1 2026 per ANTX's latest filing, from $53.1 million in the prior quarter.
• Across five years, Common Equity topped out at $139.0 million in Q3 2023 and bottomed at $53.1 million in Q4 2025.
• Historically, Common Equity has averaged $93.1 million across 5 years, with a median of $87.8 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity surged 599.31% — and 2024, when it tumbled 36.91%.
• AN2 Therapeutics' Common Equity stood at $95.4 million in 2022, then jumped by 30.75% to $124.7 million in 2023, then slumped by 34.36% to $81.8 million in 2024, then sank by 35.17% to $53.1 million in 2025, then surged by 54.09% to $81.8 million in 2026.
• Business Quant data shows ANTX's Common Equity at $81.8 million in Q1 2026, $53.1 million in Q4 2025, and $60.4 million in Q3 2025.